Head-to-head · free
Quoin Pharmaceuticals vs Rapport Therapeutics
QNRX vs RAPP — return on capital, cash generation, margins and balance sheet side by side.
QNRX
2 / 3
measures where QNRX leads
RAPP
1 / 3
measures where RAPP leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | QNRX · FY2025 | RAPP · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | (15.8M) | (111.5M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | — | (88.1M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -141.6% | -28.2% |
| Gross margin | — | — |
| Operating margin | — | — |
| Net debt / EBITDA | 0.24x | 0.42x |
Figures are as reported by each company; latest fiscal year shown.
Where Quoin Pharmaceuticals's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Rapport Therapeutics's cash went (FY2025)
- Capital spending
- $616000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free